Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27492426 | 0.88 | MAPK14 (0.53) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6030191 | 0.83 | MAPK14 (0.53) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028093 | 0.82 | MAPK14 (0.51) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL4333423 | 0.81 | MAPK14 (0.61) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028037 | 0.81 | MAPK14 (0.58) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6029116 | 0.80 | MAPK14 (0.52) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028611 | 0.80 | MAPK14 (0.59) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028029 | 0.80 | MAPK14 (0.54) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6029621 | 0.79 | MAPK14 (0.53) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6029062 | 0.78 | MAPK14 (0.52) | MAPK14SRCBRAFKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1281604-C | Substituted pyrazole compounds | TEIKOKU HORMONE MFG CO LTD (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-7087624-B2 | Substituted pyrazole compounds | TEIKOJU HORMONE MFG. CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1188754-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1560051-A | Substituted pyrazole compounds | �۹���ҩ��ʽ���� | 2005-01-05 | — | — | CN | disclosed |
| CN-1178931-C | Substituted pyrazole compounds | �۹���ҩ��ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040087628-A1 | Substituted pyrazole compounds | MINAMI NOBUYOSHI (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6667325-B1 | P38MAP kinase inhibiters; tumor necrosis factor alpha, interleukin 1 and 6 and cyclooxygenase II related diseases | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| CN-1353704-A | Substituted pyrazole compounds | TEIKOKU HORMONE MFG CO LTD (JP) | 2002-06-12 | — | — | CN | disclosed |
| EP-1188754-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087628-A1 | Substituted pyrazole compounds | CNKSR1, MAPK1, IRAK1 | MAPK14 64/4885SRC 684/4885BRAF 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.